Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells

Carcinogenesis

Volumn 27, Issue 3, 2006, Pages 508-516

  Kodach, Liudmila L ^a   Bos, Carina L ^a   Durán, Nelson ^b,d   Peppelenbosch, Maikel P ^c   Ferreira, Carmen V ^b   Hardwick, James C H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN D1; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIOLACEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CHEMOSENSITIVITY; CHROMOBACTERIUM VIOLACEUM; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; INDOLES; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33644867406     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi307     Document Type: Article

References (34)

1. Duran,N. and Menck,C.F. (2001) Chromobacterium violaceum: A review of pharmacological and industiral perspectives. Crit. Rev. Microbiol., 27, 201-222.
2. Rettori,D. and Durán,N. (1998) Production, extraction and purification of violacein: An antibiotic produced by Chromobacterium violaceum. World J. Microbiol. Biotechnol., 14, 685-688.
3. Bromberg,N. and Durán,N. (2001) Violacein transformation by peroxidases and oxidases: Implications on its biological properties. J. Mol. Catal. B Enzym., 11, 463-467.
4. Melo,P.S., Justo,G.Z., de Azevedo,M.B., Duran,N. and Haun,M. (2003) Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology, 186, 217-225.
5. Saraiva,V.S., Marshall,J.C., Cools-Lartigue,J. and Burnier,M.N.,Jr (2004) Cytotoxic effects of violacein in human uveal melanoma cell lines. Melanoma Res., 14, 421-424.
6. Duran,N., Justo,G.Z., Melo,P.S., De Azevedo,M.B., Brito,A.R., Almeida,A.B. and Haun,M. (2003) Evaluation of the antiulcerogenic activity of violacein and its modulation by the inclusion complexation with beta-cyclodextrin. Can. J. Physiol. Pharmacol., 81, 387-396.
7. Leon,L.L., Miranda,C.C., De Souza,A.O. and Duran,N. (2001) Antileishmanial activity of the violacein extracted from Chromobacterium violaceum. J. Antimicrob. Chemother., 48, 449-450.
8. Melo,P.S., Maria,S.S., Vidal,B.C., Haun,M. and Duran,N. (2000) Violacein cytotoxicity and induction of apoptosis in V79 cells. In Vitro Cell Dev. Biol. Anim., 36, 539-543.
9. Ferreira,C.V., Bos,C.L., Versteeg,H.H., Justo,G.Z., Duran,N. and Peppelenbosch,M.P. (2004) Molecular mechanism of violacein-mediated human leukemia cell death. Blood, 104, 1459-1464.
10. Jemal,A., Murray,T., Samuels,A., Ghafoor,A., Ward,E. and Thun,M.J. (2003) Cancer statistics, 2003. CA Cancer J. Clin., 53, 5-26.
11. Machover,D. (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer, 80, 1179-1187.
12. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. (1992) Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol., 10, 896-903.
13. Bouzid,K., Khalfallah,S., Tujakowski,J., Piko,B., Purkalne,G., Plate,S., Padrik,P., Serafy,M., Pshevloutsky,E.M. and Boussard,B. (2003) A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as fast-line therapy for advanced colorectal cancer. Ann. Oncol., 14, 1106-1114.
14. Giacchetti,S., Perpoint,B., Zidani,R. et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as fast-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 18, 136-147.
15. Hanahan,D. and Weinberg,R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70.
16. Johnstone,R.W., Ruefli,A.A. and Lowe,S.W. (2002) Apoptosis: A link between cancer genetics and chemotherapy. Cell, 108, 153-164.
17. Blagosklonny,M.V. (2004) Prospective strategies to enforce selectively cell death in cancer cells. Oncogene, 23, 2967-2975.
18. Carethers,J.M., Chauhan,D.P., Fink,D., Nebel,S., Bresalier,R.S., Howell,S.B. and Boland,C.R. (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology, 117, 123-131.
19. de Vos tot Nederveen Cappel,W.H., Meulenbeld,H.J., Kleibeuker,J.H., Nagengast,F.M., Menko,F.H., Griffioen,G., Cats,A., Morreau,H., Gelderblom,H. and Vasen,H.F. (2004) Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int. J. Cancer, 109, 468-471.
20. Carethers,J.M., Smith,E.J., Behling,C.A., Nguyen,L., Tajima,A., Doctolero,R.T., Cabrera,B.L., Goel,A., Arnold,C.A., Miyai,K. and Boland,C.R. (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology, 126, 394-401.
21. Chou,T.C. and Talalay,P. (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55.
22. Mayer,A.M. and Gustafson,K.R. (2003) Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int. J. Cancer, 105, 291-299.
23. Newman,D.J., Cragg,G.M. and Snader,K.M. (2003) Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66, 1022-1037.
24. Vivanco,I. and Sawyers,C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
25. del Peso,L., Gonzalez-Garcia,M., Page,C., Herrera,R. and Nunez,G. (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278, 687-689.
26. Romashkova,J.A. and Makarov,S.S. (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 401, 86-90.
27. Rayet,B. and Gelinas,C. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 18, 6938-6947.
28. Pahl,H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
29. Wang,C.Y., Cusack,J.C.Jr, Liu,R. and Baldwin,A.S.,Jr (1999) Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 5, 412-417.
30. Cusack,J.C.,Jr, Liu,R. and Baldwin,A.S.,Jr (2000) Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res., 60, 2323-2330.
31. Diehl,J.A., Cheng,M., Roussel,M.F. and Sherr,C.J. (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
32. Rossig,L., Jadidi,A.S., Urbich,C., Badorff,C., Zeiher,A.M. and Dimmeler,S. (2001) Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell Biol., 21, 5644-5657.
33. Dijkers,P.F., Birkenkamp,K.U., Lam,E.W., Thomas,N.S., Lammers,J.W., Koenderman,L. and Coffer,P.J. (2002) FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: Protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol., 156, 531-542.
34. Zhou,B.P., Liao,Y., Xia,W., Zou,Y., Spohn,B. and Hung,M.C. (2001) HER-2/ neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3, 973-982.